Open tender · Germany · Contract notice
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Doravirin + Lamivudin + Tenofovirdisoproxilfumarat, ATC J05AR24 für die Zeit 01.12.2025 - 30.11.2027
DAK-Gesundheit in Germany is inviting bids for “Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Doravirin + Lamivudin + Tenofovirdisoproxilfumarat, ATC…”. Bids close on 5 October 2027.
The work
Non-exclusive discount agreement for Doravirin + Lamivudin + Tenofovirdisoproxilfumarat (ATC J05AR24) for 1 Dec 2025 - 30 Nov 2027
- Agreement must be per contract terms in Annex 1 and 2
- Must be submitted by 5th of the preceding month for next month entry
Key facts
- Contract period
- 1 Dec 2025 - 30 Nov 2027
- Evaluation
- Selection based on offer letter
What it takes to qualify
Worth a closer look
- § 130a Absatz 8 SGB V
- Regularien des 4. Teils des GWB
- Zulassungsmodells
- offene Verfahren
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- AngebotsschreibenOffer letter in text form via email
- Anerkennung der vertraglichen Maßgaben der DAK-GesundheitSigned contract with DAK health terms
- Anlage 1 zum VertragFilled out as per contract
- Anlage 2 zum VertragExcel file with drug list
- VertragContract with name or company stamp